Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia.
Refractoriness to platelet (PLT) transfusion is a feared, life-threatening complication in hematology-oncology patients. Despite increased PLT requirement and treatment costs, the clinical management is difficult and these patients had less favorable outcomes. We report on the efficacy of the thrombopoietic agent romiplostim in a patient with acute myeloid leukemia with chemotherapy-induced transfusion-refractory thrombocytopenia. Romiplostim could be very helpfull in the management of AML patients with transfusion refractory thrombocytopenia.